[A20-63] Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2020
Commission awarded on 24.07.2020 by the Federal Joint Committee (G-BA).
Immune system and infections
|Children from 3 years to < 12 years of age with chronic hepatitis C|
|Genotype 1 and 4: hint of non-quantifiable added benefit; genotype 3, 5 and 6: added benefit not proven|
|A17-41||Ledipasvir/sofosbuvir (hepatitis C) – Benefit assessment according to §35a Social Code Book V||Commission completed|
|A14-44||Ledipasvir/sofosbuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)||Commission completed|